Table 1:

Case summaries of advanced renal cancer with adrenal metastases.

Patient characteristic	No. (%)
Median age (range)	49.5 years; range 41–80 years
Gender: male/female	12 (100%)/0 (0%)
Race: AA/CA/Hispanic	1 (8.3%)/10 (83.4%)/1 (8.3%)
Unilateral/bilateral	9 (75%)/3 (25%)
Nephrectomy	11 (91.7%)/1 (8.3%)
Histology: clear cell/translocation xp11	11 (91.7%)/1 (8.3%)
Fuhrman Grade: 2/3/unknown	5 (42%)/4 (33%)/3 (25%)
Median time to adrenal mets (range)	68 months (0–252 months)
Systemic therapy: IL-2/ICI/none/VEGF	3 (25%)/5 (41%)/3 (25%)/1 (9%)
Systemic therapy: anti-VEGF therapy	6 (50%)
Local therapy: Surgery/cryotherapy/microwave/none	3 (25%)/6 (50%)/1 (8%)/2 (17%)
IMDC risk: Fav/Int/poor	4 (33.3%)/8 (66.7%)/0 (0%)

AA, African American; CA, Caucasian; IMDC, International Metastatic Disease Consortium; Fav, favorable; Int, intermediate; IL-2, interleukin-2; ICI, immune checkpoint inhibitor; mets, metastases; VEGF, vascular endothelial growth factor.